Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 2/20 | 0.30 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA7 | P43166 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL27767877 | 0.98 | EPHX1 (0.31) | EPHX1MAPTHPGD | |
| Hydrochloric Acid SCHEMBL27567194 | 0.89 | MAPT (0.33) | MAPT | |
| SCHEMBL18480410 | 0.88 | EPHX1 (0.32) | EPHX1CA12CA14CA1CA7 | |
| Hydrochloric Acid SCHEMBL6428582 | 0.88 | MAPT (0.33) | MAPT | |
| Betaine SCHEMBL1302591 | 0.86 | TSHR (0.45) | — | |
| Water SCHEMBL4106014 | 0.82 | GAA (0.40) | HPGD | |
| SCHEMBL12866625 | 0.80 | CA1 (0.51) | CA12CA14CA1CA7CA2 | |
| Water SCHEMBL3597496 | 0.78 | MEN1 (0.39) | — | |
| SCHEMBL2888595 | 0.77 | — | — | |
| SCHEMBL1693442 | 0.76 | ALDH1A1 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 789 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4410788-B1 | CYANO COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI INST MATERIA MEDICA CAS (CN) | 2026-03-04 | — | — | EP | claimed |
| WO-2025081982-A1 | PREPARATION METHOD FOR FINERENONE KEY INTERMEDIATE | 山东诚创蓝海医药科技有限公司 | 2025-04-24 | — | — | WO | claimed |
| WO-2024256574-A1 | PROCESS FOR PREPARING MACROCYCLIC BTK INHIBITORS | CROSSFIRE ONCOLOGY HOLDING B.V. (NL) | 2024-12-19 | — | — | WO | claimed |
| CN-114269744-B | Methods for preparing Toll-like receptor modulator compounds | 吉利德科学公司 | 2024-10-18 | — | — | CN | claimed |
| EP-4410788-A1 | CYANO COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2024-08-07 | — | — | EP | claimed |
| WO-2023051657-A1 | CYANO COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 中国科学院上海药物研究所 | 2023-04-06 | — | — | WO | claimed |
| US-20220298226-A1 | METHACRYLATED COLLAGEN | JELLAGEN LTD (GB) | 2022-09-22 | — | — | US | claimed |
| EP-3990455-A1 | PROCESSES FOR PREPARING TOLL-LIKE RECEPTOR MODULATOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2022-05-04 | — | — | EP | claimed |
| EP-3986489-A1 | METHACRYLATED COLLAGEN | Jellagen Limited (GB) | 2022-04-27 | — | — | EP | claimed |
| CN-114269744-A | Methods for preparing Toll-like receptor modulator compounds | 吉利德科学公司 | 2022-04-01 | — | — | CN | claimed |
| EP-1678169-B1 | 4-(PYRAZOL-3-YLAMINO)PYRIMIDINE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2009-07-22 | — | — | EP | claimed |
| EP-1778220-A1 | CONSTRAINED CYANO COMPOUNDS | Phenomix Corporation (US) | 2007-05-02 | — | — | EP | claimed |
| CN-1894243-A | 4- (pyrazol-3-ylamino) pyrimidine derivatives for the treatment of cancer | ASTRAZENECA AB (SE) | 2007-01-10 | — | — | CN | claimed |
| EP-1303514-B9 | PROCESS FOR PREPARING AZACYCLOALKANOYLAMINOTHIAZOLES | BRISTOL MYERS SQUIBB CO (US) | 2006-11-08 | — | — | EP | claimed |
| WO-2006017292-A1 | CONSTRAINED CYANO COMPOUNDS | PHENOMIX CORPORATION (US) | 2006-02-16 | — | — | WO | claimed |
| US-20060009518-A1 | Constrained cyano compounds | Forest Laboratories Holding Limited (BM) | 2006-01-12 | — | — | US | claimed |
| CN-1227250-C | Process for preparing azacycloalkanoylaminothiazoles | BRISTOL MYERS SQUIBB CO (US) | 2005-11-16 | — | — | CN | claimed |
| EP-1303514-B1 | PROCESS FOR PREPARING AZACYCLOALKANOYLAMINOTHIAZOLES | BRISTOL MYERS SQUIBB CO (US) | 2005-07-20 | — | — | EP | claimed |
| CN-1449395-A | Process for preparing azacycloalkanoylaminothiazoles | BRISTOL MYERS SQUIBB CO (US) | 2003-10-15 | — | — | CN | claimed |
| EP-0880541-B1 | DERIVATIVES OF ANTIBIOTIC GE2270 FACTORS | BIOSEARCH ITALIA SPA (IT) | 2003-01-15 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060009518-A1 | Constrained cyano compounds | DNPEP, PREP, PEPD | EPHX1 1922/4885MAPT 4255/4885HPGD 851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.